|
|
(5 intermediate revisions by 2 users not shown) |
Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| {{Atorvastatin}}
| | {{CMG}} |
| {{CMG}}; {{AE}} {{PB}} | |
|
| |
|
| '''''For patient information, click [[Atorvastatin (patient information)|here]]'''''.
| | ===[[Atorvastatin calcium]] ([[Atorvastatin calcium|Lipitor]])=== |
| | ===[[Amlodipine besylate/Atorvastatin calcium]]=== |
| | ===[[Amlodipine/Atorvastatin]]=== |
| | ===[[Ezetimibe/Atorvastatin]]=== |
|
| |
|
| ==Overview== | | ==Overview== |
|
| |
|
| Atorvastatin is a member of the drug class known as [[statins]], used for lowering blood [[cholesterol]]. It also stabilizes plaque and prevents [[stroke]]s through anti-inflammation and other mechanisms. Like all statins, atorvastatin works by inhibiting [[HMG-CoA reductase]], an enzyme found in liver tissue that plays a key role in production of [[cholesterol]] in the body. | | Atorvastatin is a HMG-COA Reductase Inhibitor drug that is FDA approved for the treatment of hyperlipidemia, prevention of cardiovascular disease. Adverse reactions include [[diarrhea]], [[arthralgia]], [[myalgia]], urinary tract infectious disease, [[nasopharyngitis]], pain, in extremity. |
|
| |
|
| ==Category== | | ==Category== |
|
| |
|
| Lipid-Lowering Agents, Statins
| | HMG-COA Reductase Inhibitor |
| | |
| ==US Brand Names==
| |
| | |
| Lipitor<sup>®</sup>
| |
| | |
| ==FDA Package Insert==
| |
| | |
| ''' [[Atorvastatin indications and usage|Indications and Usage]]'''
| |
| '''| [[Atorvastatin dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Atorvastatin contraindications|Contraindications]]'''
| |
| '''| [[Atorvastatin warnings|Warnings and Precautions]]'''
| |
| '''| [[Atorvastatin adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Atorvastatin overdosage|Overdosage]]'''
| |
| '''| [[Atorvastatin description|Description]]'''
| |
| '''| [[Atorvastatin clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Atorvastatin clinical studies|Clinical Studies]]'''
| |
| '''| [[Atorvastatin how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Atorvastatin labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action==
| |
| | |
| Atorvastatin is a selective, competitive inhibitor of [[HMG-CoA reductase]], the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to [[mevalonate]], a precursor of [[cholesterol]].
| |
| | |
| In animal models, atorvastatin lowers plasma cholesterol and [[lipoprotein]] levels by inhibiting [[HMG-CoA reductase]] and [[cholesterol]] synthesis in the liver and by increasing the number of hepatic [[LDL receptor]]s on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces [[LDL]] production and the number of [[LDL]] particles. Atorvastatin reduces [[LDL]]-C in some patients with homozygous [[familial hypercholesterolemia]] (FH), a population that rarely responds to other lipid-lowering medication(s).
| |
| | |
| Atorvastatin reduces total-C, [[LDL]]-C, and [[apo B]] in patients with homozygous and heterozygous FH, nonfamilial forms of [[hypercholesterolemia]], and mixed [[dyslipidemia]].
| |
| | |
| Atorvastatin also reduces [[VLDL]]-C and [[TG]] and produces variable increases in [[HDL]]-C and apolipoprotein A-1.
| |
| | |
| Atorvastatin reduces total-C, [[LDL]]-C, [[VLDL]]-C, [[apo B]], [[TG]], and non-[[HDL]]-C, and increases [[HDL]]-C in patients with isolated [[hypertriglyceridemia]].
| |
| | |
| Atorvastatin reduces intermediate density [[lipoprotein]] [[cholesterol]] ([[IDL]]-C) in patients with [[dysbetalipoproteinemia]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228#nlm34089-3 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |